Covid 19 Pandemisi Sırasında Kullanılan Farmakolojik Ajanların Gözden Geçirilmesi.
A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.

Fikriye Yasemin ÖZATİK


2019 Aralık ayından itibaren Çin’de bir dizi pnomöni vakası bildirildi. Dünya Sağlık örgütü yapılan bir dizi araştırmadan sonra 11 Şubat 2020 de 2019- nCoV’un neden olduğu bu hastalığı koronavirüs hastalığı (COVID-19) olarak adlandırdı. COVID-19 küresel bir salgındır. Bu derlemede COVID-19 pandemisinde kullanılan ilaçların farmakokinetik ve farmakodinamik olarak değerlendirilmesi amaçlanmıştır. COVID-19 pandemisinde kullanılan ilaçlar ile ilgili kanıtlar henüz kesin değildir. Bu ilaçlar ile ilgili daha çok çalışmaya ve daha çok bilgiye ihtiyaç duyulmaktadır.
A number of pneumonia cases have been reported in China since December 2019. After a series of researches, the World Health Organization named this disease caused by 2019- nCoV on 11 February 2020 as coronavirus disease (COVID-19). COVID-19 is a global pandemic. The aim of this review was to evaluate the pharmacokinetics and pharmacodynamics of the drugs used in COVID-19 pandemic Evidence for eficacy of the drugs used in the COVID-19 pandemic is not yet clear. Further studies and information are needed on these drugs.
  • Referans 1: Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr 2020; 63(4):119-124. DOI: 10.3345/cep.2020.00493.
  • Referans 2: Kim KH. COVİD-19. Int Neurourol J 2020; 24(1):1.
  • Referans 3: Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Le Infezioni in Medicina, 2020; 2; 198-201.
  • Referans 4: Aguiar ACC, Murce E, Cortopassi WA, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 2018; 8(3):459-464.
  • Referans 5: Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J. Gen. Virol 1969; 4: 203-2014.
  • Referans 6: Keyaerts E, Li S, Vijgen L, Verbeeck J, Van Ranst M, Maes P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53: 3416-3421.
  • Referans 7: Tan YW, Yam WK, Sun J, Chu JJI. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antivir. Res 2018; 149: 143-149.
  • Referans 8: Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 2017; 24: 189-194.
  • Referans 9: Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013; 23:300-302.
  • Referans 10: Paton NI, Lee L, Xu Y, et al. Smith. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect. Dis 2011; 11:677-683.
  • Referans 11: Delogu I, de Lamballerie X. Chikungunya disease and chloroquine treatment. J. Med. Virol 2011; 83: 1058-1059.
  • Referans 12: Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr. Opin. Rheumatol 2011; 23: 278-281.
  • Referans 13: Şimşek Yavuz S, Ünal S. Antiviral Treatment of COVID-19. Turk J Med Sci 2020; 21;50(SI-1):611-619.
  • Referans 14: Schrezenmeie T, Dörner E. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology 2020; 16:155–166.
  • Referans 15: . Lu YL, Chen CC, Chang MY. Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association 2020; 83(6):534-536.
  • Referans 16: Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020; doi: 10.1093/cid/ciaa237
  • Referans 17: Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. Clinical Trial 2020; 24;3(4):e208857.
  • Referans 18: Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua jie he he hu xi za zhi 2020; 43(3):185–8.
  • Referans 19: Barlow A, Landolf KM, Barlow B, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy 2020; 40(5): 416–437.
  • Referans 20: Concordia Pharmaceuticals Inc. Plaquenil (hydroxychloroquine) package insert. St. Michael: Concordia Pharmaceuticals Inc; 2017.
  • Referans 21: Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Research 2020; 177; 104762.
  • Referans 22: Sanofi‐Aventis USLLC. Aralen (Chloroquine phosphate) package insert. Bridgewater, NJ: Sanofi‐Aventis USLLC; 2017.
  • Referans 23: de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci 2020; 117:6771-6776.
  • Referans 24: Sheahan TP, Sims AC, Leist SR. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11:222.
  • Referans 25: Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients With Severe Covid-19. N Engl J Med 2020; 11;382(24):2327-2336
  • Referans 26: Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9.pii: e00221-18. doi: 10.1128/mBio.00221-18.
  • Referans 27: Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid Review for the Anti-Coronavirus Effect of Remdesivir. Drug Discov Ther 2020; 14(2):73-76.
  • Referans 28: Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531:381-385.
  • Referans 29: Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269-271.
  • Referans 30: Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382:929-936.
  • Referans 31: Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid 19. N Engl J Med 2020; doi: 10.1056/NEJMoa2007016.
  • Referans 32: Furuta Y, Gowen BB, Takahashi K, Shiraki G, Smee BF, Barnard DL. Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor. Antiviral Res 2013, 100(2):446-54.
  • Referans 33: Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection. Clin Pharmacol Ther 2020; doi: 10.1002/cpt.1844.
  • Referans 34: Wang Y, Guohui F, Salam A, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J. Infect. Dis 2020; 323(11):1061-1069.
  • Referans 35: Madelain, V, Nguyen THT, et al. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 2016; 55, 907– 923.
  • Referans 36: Cai, Q, Yang M, Liu D, Shu D, Xia J, Liao X, et al. Experimental treatment with Favipiravir for COVID‐19: an open‐label control study. Engineering 2020; https://doi.org/10.1016/j.eng.2020.03.007.
  • Referans 37: Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J. Clin. Pharmacol 2004; 44, 7– 19.
  • Referans 38: Renwick AB, Ball SE, Tredger JM, et al. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision‐cut liver slices. Xenobiotica 2002; 32, 849– 862.
  • Referans 39: Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11:222.
  • Referans 40: Zumla A, Chan JF, Azhar EI, Hui DSC, Yuen YK. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15:327–347.
  • Referans 41: Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020; 55(5): 105951.
  • Referans 42: van der Laan LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, Wiesner L. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 2018; 62(2): e00420-17.
  • Referans 43: Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42(7):1048-59.
  • Referans 44: Mary B. Wire, Heidi B. McLean, Pendry C, Theodore D, Park JW, Peng B. Assessment of the Pharmacokinetic Interaction between Eltrombopag and Lopinavir-Ritonavir in Healthy Adult Subjects. Antimicrob Agents Chemother 2012; 56(6): 2846–2851.
  • Referans 45: Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acquir. Immune Syndr 2008; 47:570–578.
  • Referans 46: Gamiño‐Arroyo AE, Guerrero ML, McCarthy S, et al. Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin Infect Dis 2019; 69(11):1903–11.
  • Referans 47: Musarrat F, Chouljenko V, Dahal A, et al. The anti-HIV Drug Nelfinavir Mesylate (Viracept) Is a Potent Inhibitor of Cell Fusion Caused by the SARSCoV-2 Spike (S) Glycoprotein Warranting Further Evaluation as an Antiviral Against COVID-19 Infections. J Med Virol 2020; 6:10.1002/jmv.25985.
  • Referans 48: Agouron Pharmaceuticals Inc. Viracept (nelfinavir mesylate) package insert. La Jolla, CA: Agouron Pharmaceuticals Inc; 2005.
  • Referans 49: Hama R. The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis 2016; 48(9):651-60.
  • Referans 50: Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11):1061–1069.
  • Referans 51: Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; doi: 10.1001/jama.2020.6019.
  • Referans 52: Cameron MJ, Bermejo‐Martin JF, Danesh A, Muller MP, Celvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2008; 133(1):13–9.
  • Referans 53: Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507–13.
  • Referans 54: Xu X, Han M, Li T, et al. Effective treatment of severe COVID‐19 patients with Tocilizumab. Proc Natl Acad Sci USA 2020; 19;117(20):10970-10975.
  • Rerans 55: Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10(7):676–8.
  • Referans 56: Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197(6):757-767.
  • Referans 57: Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 2019; 23(1):99.
  • Referans 58: Zha L, Li S, Pan L, et al. Corticosteroid Treatment of Patients With Coronavirus Disease 2019 (COVID-19). Med J Aust 2020; 212(9):416-420.
  • Referans 59: Jean SS, Lee PI, Hsueh PR. Treatment Options for COVID-19: The Reality and Challenges. J Microbiol Immunol Infect 2020; 53(3):436-443.
  • Referans 60: Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; DOI: 10.1016/j.ijantimicag.2020.10594.
  • Referans 61: Uddin M, Mustafa F, Rizvi TA, et al. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses 2020; DOI: 10.3390/v12050526.
  • Referans 62: Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020; 52(4):583–589.
  • Referans 63: Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines 2020; 5:1–3.
  • Referans 64: COVID-19 vaccine tracker. Milken Institute. 11 December 2020. Airtable - Milken Institute
  • Referans 65: Draft landscape of COVID 19 candidate vaccines". World Health Organization. 11 December 2020. Draft landscape of COVID-19 candidate vaccines (who.int)
Birincil Dil en
Konular Tıp
Yazarlar

Orcid: 0000-0002-8422-2975
Yazar: Fikriye Yasemin ÖZATİK (Sorumlu Yazar)
Kurum: KÜTAHYA SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ
Ülke: Turkey


Tarihler

Yayımlanma Tarihi : 2 Mart 2021

Bibtex @derleme { aemj805416, journal = {Ahi Evran Medical Journal}, issn = {}, eissn = {2619-9203}, address = {Ahi Evran Üniversitesi Tıp Fakültesi Bağbaşı Yerleşkesi Merkez / KIRŞEHİR}, publisher = {Ahi Evran Üniversitesi}, year = {}, pages = { - }, doi = {10.46332/aemj.805416}, title = {A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.}, key = {cite}, author = {Özatik, Fikriye Yasemin} }
APA Özatik, F . (). A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic. . Ahi Evran Medical Journal , , . DOI: 10.46332/aemj.805416
MLA Özatik, F . "A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic." . Ahi Evran Medical Journal ( ): <https://dergipark.org.tr/tr/pub/aemj/article/805416>
Chicago Özatik, F . "A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.". Ahi Evran Medical Journal ( ):
RIS TY - JOUR T1 - A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic. AU - Fikriye Yasemin Özatik Y1 - 2021 PY - 2021 N1 - doi: 10.46332/aemj.805416 DO - 10.46332/aemj.805416 T2 - Ahi Evran Medical Journal JF - Journal JO - JOR SP - EP - SN - -2619-9203 M3 - doi: 10.46332/aemj.805416 UR - https://doi.org/10.46332/aemj.805416 Y2 - 2021 ER -
EndNote %0 Ahi Evran Tıp Dergisi A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic. %A Fikriye Yasemin Özatik %T A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic. %D 2021 %J Ahi Evran Medical Journal %P -2619-9203 %R doi: 10.46332/aemj.805416 %U 10.46332/aemj.805416
ISNAD Özatik, Fikriye Yasemin . "A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.". Ahi Evran Medical Journal - . https://doi.org/10.46332/aemj.805416
AMA Özatik F . A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.. Ahi Evran Med J. -.
Vancouver Özatik F . A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.. Ahi Evran Medical Journal. -.
IEEE F. Özatik , "A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.", Ahi Evran Medical Journal, doi:10.46332/aemj.805416